Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients
Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.
How this was made
The 30-second read
Why it matters
The partnership targets cardiovascular patients with obstructive sleep apnea and insomnia, aiming to address a shortage of board-certified sleep medicine specialists via an integrated diagnostic and treatment framework aligned with cardiology groups.
Market read
A new physician-aligned services expansion model for OSA/insomnia care in CVD patients, with Vivos as the controlling partner, could influence investor expectations for scalable growth.
What to watch
Key missing details are reimbursement economics, expected patient throughput, regulatory approval timing for AIM Florida, and whether the model materially changes VVOS margins versus existing service lines.
Background
Vivos focuses on breathing-related sleep disorders; SPCVA is a multi-location cardiology practice in Florida with ~30,000 patients.
Ticker impact
Vivos entered a collaboration with SPCVA to form AIM Florida, expanding integrated OSA/insomnia care for cardiovascular patients, with Vivos holding at least 80%.
Near-term reaction could be modest-to-positive if investors view the model as repeatable without large capital outlays; follow-through depends on regulatory documentation and rollout execution.
The article discloses a new collaboration structure and ownership split, but provides no financial terms, patient volumes, or timeline beyond initial Palm Beach County focus.
Market effects
Supports the broader read-through that sleep-disorder care can be bundled with cardiology pathways, potentially strengthening demand for sleep-focused providers/devices and services platforms.
Florida cardiology practices may see increased referral/diagnostic capacity for OSA/insomnia in CVD patients, starting in Palm Beach County.
Limited direct global impact; relevance is mainly as a US expansion template for integrated care models.
Counterpoint
The agreement may be more operational/management-services than revenue-generating in the near term, with unclear economics and regulatory/documentation gating.
Key entities
- companyVivos Therapeutics, Inc.
Sleep-disorder medical device and healthcare services company entering the AIM Florida collaboration.
- companySouth Palm Cardiovascular Associates, LLC (SPCVA)
Florida cardiology practice partnering to form AIM Florida for integrated sleep-disorder care in CVD patients.
- entityAIM Florida, LLC
Physician-aligned management services organization created under the collaboration; Vivos expects to hold at least 80%.
